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Abstract 
 
Malaria is a deadly disease in sub-tropical and tropical regions. Despite extensive 
development in treatment options, it continues to be a major burden due to development of 
resistance to medications that are currently available. This has led to a demand for the 
production of more efficient, alternative antimalarial drugs. Dichloromethane was used to 
extract the stem-bark of Warburgia salutaris, a medical plant, used by Zulu traditional 
healers to treat malaria and a compound was isolated by column chromatography. Mukaadial 
Acetate (M. acetate) was identified and characterized by spectroscopic analysis (
1 
H NMR, 
13
 
C NMR, IR and MS) and the structure was confirmed by X-ray crystallography. A 
chloroquine-sensitive Plasmodium falciparum strain was used to test in vitro antiplasmodial 
activity. The MTT assay was used to measure the cytotoxicity of W. salutaris and Mukaadial 
Acetate on HEK239 and HEPG2 cell lines. Molecular docking of the compound was 
conducted using AutoDock Vina (www.vina.scripps.edu). UCSF Chimera 
(www.cgl.ucsf.edu) was used for structural modifications and LigPlot was used to examine 
molecular interactions. Antiplasmodial studies (in vivo) were carried out using chloroquine-
sensitive rodent malaria parasite, Plasmodium berghei, in Sprague-Dawley rats. Mukaadial 
Acetate and the crude extract were administered orally at 0.5; 1.5, 2.5 and 5mg/kg, 
chloroquine p.o. was used as the reference drug. Determination of percentage parasitemia, 
haematological parameters, and rat body weights was done throughout the experimental study 
period. 
The crude extract inhibited parasite growth (IC 50 0.01±0.30 µg/ml). The compound, 
Mukaadial Acetate also exhibited activity (IC 50 0.44±0.10 µg/ml) against the parasite 
growth. Mukaadial acetate had a cytotoxicity activity of 36.7 ± 0.8 and 119.2 ± 8.8 (µg/ml) 
on HEK293 and HEPG2 cells respectively. 
Docking showed that Mukaadial Acetate binds to the pyrophosphate, purine and ribose 
binding sites of the PfHGXPRT with an optimum binding conformation and forms steric and 
hydrophobic interactions as well as hydrogen bonds with the residues inhabiting the 
respective binding sites. The crude extract and the pure W. salutaris compound reduced 
percentage parasitemia in a dose-dependent manner in comparison to the control. There were 
no significant differences in the hematological parameters in all the experimental groups in 
comparison to control group. 
It is evident that W. salutaris possesses constituents (including Mukaadial Acetate) that 
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display antiplasmodial properties. The current study scientifically validates the use of W. 
salutaris in traditional medicine. 
Keywords: Plasmodium falciparum; antimalarial activity; Warburgia salutaris; Mukaadial 
Acetate; molecular docking; PfHGXPRT; Plasmodium berghei. 
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1. Chapter One 
 
1.1. Introduction to malaria 
 
Malaria is a deadly disease caused by parasitic protozoa of the Plasmodium genus. There are 
five, human malaria causing Plasmodium species, i.e. Plasmodium vivax; Plasmodium ovale; 
Plasmodium malariaea; Plasmodium knowlesi and Plasmodium falciparum [1]. The species 
differ in shape and size, pathogenic pattern, geographic distribution and resistance 
development [2]. P. vivax and P. falciparum are considered the most lethal [1]. The parasite 
is transmitted by a bite from a female Anopheles mosquito [1].  
Malaria is prevalent in tropical and sub-tropical regions. In the year 2015, 3.2 billion people 
were at risk of malaria worldwide and from these, an estimated 438 000 deaths were reported 
[4]. Although the World Health Organisation (WHO) has reported a decrease in malaria cases 
and deaths from 2000-2015 [1], there is still an increasing panic due to the emerging 
resistance of some P. falciparum strains against the most prevalent malaria treatments [3]. 
 A large majority (90%) of malaria caused fatalities in 2015 were found to be in Sub-Saharan 
Africa [4]. This is due to lack of effective medical treatment for some diseases such as 
malaria and/or HIV/AIDS, which, although globally distributed, affect Africa more than other 
areas in the world [5]. Literature indicates that due to this inaccessibility of western 
medicines in parts of the continent, a large majority of the African population mainly depend 
on traditional medicine as their primary health care provider [5]. 
Traditional healing has been practised for centuries. Traditional healers use plants, among 
other materials, with medicinal properties to treat and control various diseases. Traditional 
medicines are the source of the two main groups of current antimalarial drugs (artemisinin 
and quinine derivatives [5]. Scientists have been encouraged to look into indigenous 
medicinal plants for novel drugs of phytochemical origin as they provide potential 
pharmaceutical importance [68]. Research on traditional healers and malaria has led to the 
recognition of Warburgia salutaris plant parts as a potential malaria treatment. With 
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consideration of the extensive use of W. salutaris by Zulu traditional healers against malaria, 
this study was done to determine the antimalarial properties of this plant. [33] 
1.2. Structure of dissertation 
 
1. Chapter 1- Consists of a brief introduction and background of the research, centring 
on the target of the study.  
2. Chapter 2- Lays out the background and current knowledge on malaria, including 
research, which has been done around the subject of this study. It also includes the 
aim and objectives of this study.   
3. Chapter 3- Provides the methodology and some equipment used to collect data 
4. Chapter 4- Consists of the results obtained in the study 
5. Chapter 5- Consists of the discussion of the research findings, in contrast to literature. 
6. Chapter 6- Provides the conclusion of the study based on the results obtained. 
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2. Chapter two 
 
2.1. Malaria distribution 
 
Malaria parasite survival and distribution mainly depends on factors of the climate. This 
disease is transmitted in subtropical and tropical areas, where Anopheles mosquitoes thrive 
and where the parasites can complete their mosquito growth cycle [61]. 
Temperature is very critical, as Plasmodium falciparum, which causes severe malaria, cannot 
complete its growth cycle at temperatures below 20
o
C, and thus cannot be transmitted [61]. 
The map below shows an estimation of malaria transmission, worldwide [61]. 
 
Figure 2.1: Map depicting the distribution of malaria in the world [61]. 
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2.2. Lifecycle of the malaria parasite  
 
Human malaria infection begins with a bite of an infected Anopheles mosquito. Where viable 
sporozoites are released into the bloodstream through saliva and invade liver cells [4], once, 
inside the hepatocytes, they undergo asexual multiplication to produce merozoites. The 
merozoites are released into the bloodstream and enter red cells, where they form 
characteristic rings (ring stage) which grow into mature trophozoites and go through asexual 
multiplication to form merozoites. The RBCs rupture releasing merozoites, which then 
invade other RBCs and begin a new cycle. The growth phase of the malaria parasite within 
the RBCs is 48-72 hours depending on the species, producing periodic fevers with continuous 
releases of the merozoites [6]. Some parasites develop in the RBCs to become male and 
female gametocytes (Figure 1). There is increased virulence and complications associated 
with P. falciparum species, which are due to the sequestration of infected erythrocytes in 
deep tissues [6]. 
Clinical symptoms of malaria include chills, delirium, fever, metabolic acidosis, multi-organ 
system failure, prostration and anaemia, cerebral anaemia, followed by coma and death, in 
pregnancy, symptoms may result in maternal and foetal deaths   [7]. 
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Figure 2.2: Plasmodium parasite  life cycle [51] 
 
2.3. Pathogenesis of malaria 
 
When entering the human body from the body of a mosquito, there is a drastic change in 
environmental temperature for the parasite. Under normal circumstances the parasite would 
be destroyed, however, studies have shown that the P. falciparum parasite relies on heat 
shock proteins to survive this and other challenges the host presents [62]. Heat shock proteins 
(Hsps) are a class of molecular chaperones as they assist in the folding of other proteins in a 
cell. Some Hsps are expressed in response to cellular stress so as to facilitate protein folding 
in unfavourable conditions [69]. 
Heat shock protein 70 (Hsp70) and Hsp90 are the two prominently expressed chaperone 
proteins in P. falciparum [63]. These two proteins have been associated with development 
and pathogenesis in the blood stage of malaria. It has been suggested that they may also play 
a part in parasite drug resistance [63].  
Hsp70 is one of the most common heat shock proteins in eukaryotic cells, with an ATP 
dependent function [70]. It switches between a low-affinity ATP binding state, where it binds 
to the peptide substrate allowing it to refold and then switches to a high-affinity ATP binding 
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state, releasing the substrate [71]. Studies have shown Hsp70 to have homologs of distinct 
forms found in various organelles. This is advantageous to the parasite as the functionally 
specialised Hsp 70s facilitate parasite survival [71]. This protein functions with chaperones 
such as Hsp90 and Hsp40. The relationship between Hsp70 and Hsp40 has not been studied 
in its entirety and is thus not fully understood [72].  
Hsp90 is one of the chaperones known to be produced by the malaria parasite. It does not 
only work with its co-chaperones to assist newly synthesized proteins fold properly, it also 
assists with the regulation of transcription factors and protein kinases activity [73]. The latter 
function places Hsp90 at the centre of signal transduction within a cell, which is essential for 
its growth and survival [73]. Hsp70 and Hsp90 co-function in the folding of kinases and 
steroid hormone receptors, the association of these two is via an adaptor protein called the 
Hsp70-Hsp90 organising protein (Hop) [69]. Heat shock proteins have raised interest as drug 
targets since they are highly conserved proteins, they do not evolve as non-conserved 
proteins, which reduces the chance of drug resistance [74].  
 
2.3.1. Digestion of haemoglobin 
During infection, parasite multiplication is manifold, demanding a multitude of resources 
from the host to support its growth [8].  
During the parasite growth phase in the erythrocytes, the parasite utilizes haemoglobin, from 
the early ring-from stage. The trophozoite is unable to metabolize haemoglobin completely, 
inside the food vacuole, as it does not have the enzyme heme-oxygenase, which is used by 
vertebrates for heme catabolism [9]. Proteolytic enzymes, called falcipains (serine proteases) 
and plasmepsins (aspartic proteases), mediate this metabolic process [10]. These enzymes are 
promising targets for drug discovery since haemoglobin digestion is vital for parasite 
survival. Ten aspartic proteases have been identified in the P. falciparum genome [11], four 
of which are found in the food vacuole. These four enzymes (plasmepsin I, II, IV and 
histoaspartic protease) are involved in heme digestion and differ in sequence specificity 
cleavage sites.  Andrews et al (2007) discovered that individual knockout of each of these 
vacular aspartic proteases and the serine protease falcipain-2 demonstrate no effect on 
parasite growth. Furthermore, they revealed that accumulative knockout of the aspartic 
proteases and falcipan-2 enzymes, as well as the triple knockout of plasmepsin I/IV and 
falcipains-2, results in tempered growth of the P. falciparum parasite, which suggests that 
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combined inhibition of both aspartic proteases and serine proteases is toxic for the parasite. 
Therefore, novel inhibitors of the proteases from the parasite may serve as drugs for the 
treatment of malaria. [12] 
 
 The heme ion is very lethal to the parasite, but instead of being expelled from the RBC after 
separation from globin, heme is sequestered in the cell by being transformed into an insoluble 
form known as hemozoin. This appears as brown crystals in the digestive vacuole of the 
parasite [13]. The amount and the dimensions of the crystals in the RBC depend on the stage 
of the parasite development, with the least amount of the hemozoin detected in the ring stage 
and the highest amount in the schizont stage [14]. 
 
2.3.2. Purine salvage 
 
P. falciparum is unable to produce its own purines. Instead it relies on purines of the host cell 
for biosynthesis of nucleic acids and cofactors [15]. Erythrocytes have mill molar 
concentrations of ADP and AMP in equilibrium with ATP, therefore the parasite has had no 
need to develop pathways for purine synthesis. Purine nucleosides and nucleobases are 
transported through the parasite membrane via the P. falciparum nucleoside transporter 1 
(NT1) transporter Fig. (2.3). Mechanisms by which the parasite salvages purine during the 
blood stage differ in primary sources and routes of transformation. The main precursor for all 
purine synthesis in the metabolism of P. falciparum is Hypoxanthine. In vivo hypoxanthine is 
sourced from the erythrocyte purine pool, where ATP is in constant metabolic exchange with 
hypoxanthine through ADP, AMP, IMP, inosine and adenosine [16].  
 
Human red blood cells are also unable to synthesize their own purine, the action of adenosine 
kinase (AK) helps to maintain adenine nucleotide pools by recovering adenosine from 
plasma. This action keeps erythrocytic adenosine concentrations low and since Plasmodium 
does not possess the enzyme adenosine kinase, P. falciparum salvages the adenosine from the 
erythrocytes by converting it to hypoxanthine using the sequential activities of adenosine 
deaminase (ADA) and purine nucleoside phosphorylase (PNP). The transport of the majority 
of purine nucleosides and bases via the P. falciparum membrane is by the NT1 transporter 
Fig. (2.3). The hypoxanthine then gets transformed to IMP by hypoxanthine-guanine- 
xanthine phosphoribosyltransferase (HGXPRT). Inosine 5’-Monophosphate serves as the 
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metabolic precursor for all purine deoxynucleotides and nucleotides required for DNA/RNA 
synthesis. HGXPRT, ADA and PNP are highly expressed proteins in Plasmodium [17]. The 
parasite is unable to directly convert adenosine to AMP since it does not have an adenosine 
kinase gene in its genome. However, metabolic analysis showed that P. falciparum is able to 
utilise AMP synthesized in the erythrocyte cytosol when high concentrations of exogenous 
adenosine are used to influence erythrocytic AMP production. [19] 
 
 
Figure 2.3:  Purine salvage pathway in a Plasmodium  falciparum infected-erythrocyte [85].  
 
2.4. Treatment of Malaria 
 
The choice of treatment is dependent on the level of infection and the type of strain. WHO 
recommends artemisinin-based combination therapies (ACTs) as treatment of non-severe P. 
falciparum malaria. The combination of two drugs with different mechanisms of action, 
makes ACTs the most effective currently available antimalarial treatment. There are five 
ATCs currently recommended by WHO for use against P. falciparum malaria. Results of 
therapeutic efficacy studies against local P. falciparum strains should dictate the choice of 
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ATC to be used [22]. People with severe malaria cases must first be treated intravenously or 
intramuscularly with Artesunate for a minimum of 24 hours until the patient is able to tolerate 
oral medication. Once the oral medication is tolerable, ACT treatment must be completed 
within 3 days, with single dose primaquine in areas of low transmission [22]. Although there 
are some effective treatment methods, the development of resistant strains is still a burden. 
Table 2.4 below shows targets and structures of some currently used antimalarial drugs. 
 
2.4.1. Current anti-malarial drugs and their mechanisms of action 
 
a) Chloroquine 
This drug functions by inhibiting parasite DNA/RNA synthesis and causing rapid degradation 
of ribosomes. It accumulates in high concentrations in the parasite digestive vacuole. Once in 
the vacuole, chloroquine inhibits the detoxification of heme, by binding to it, thus leading to 
heme build-up. Toxic heme-chloroquine complex and heme promote cell lysis and eventually 
the auto-digestion of the parasitic cell. In other words, the parasitic cell drowns in its own 
metabolic products [23]. 
Resistance results in reduced accumulation of the chloroquine in the digestive vacuole [24]. 
Studies suggest that chloroquine resistance is due to reduced affinity of chloroquine for heme, 
thereby reducing chloroquine uptake by the parasite food vacuole [25]. 
 
b) Quinine 
Quinine is used to treat uncomplicated as well as severe malaria in several therapeutic 
regimens and functions in a similar way to chloroquine but has a lower affinity for heme [23].  
 
c) Artemisinin  
Artemisinin falls under the antifolate antimalarial drugs. These drugs interfere with folate 
metabolism, a pathway essential to malaria parasite survival. Resistance is triggered by point 
mutations in the two key enzymes of the folate biosynthetic pathway, which are targeted by 
antifolates [23]. Artemisinin and its derivatives are sesquiterpene lactones, which treat 
malaria by interacting with iron or heme, disintegrating into free radicals inside the parasite. 
Unfortunately, artemisinin resistance is constantly increasing [23]. 
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d) Tetracycline 
Cyclines are a form of antibiotic that act by inhibiting parasite protein synthesis. In 
Plasmodium, it is suggested that tetracycline may inhibit mitochondrial protein synthesis and 
decrease the activity of dihydroorotate dehydrogenase, a mitochondrial enzyme used for 
pyrimidine synthesis. Doxycycline blocks the production of nucleotides and 
deoxynucleotides in P. falciparum; it specifically targets the apicoplast of the parasite in two 
stages, one being with an immediate non-specific toxic effect on the apicoplast and the 
second being a characteristic cell death. Among the tetracycline family, doxycycline is the 
clinically recommended anti-malarial prophylaxis [64]. 
 
e) Atovaquone 
This is an antimalarial drug used in both prevention and treatment of malaria. It acts by 
inhibiting the cytochrome c complex of the parasite, in the electron transport chain, and in 
that way collapsing the mitochondrial membrane potential. Since the malarial ETC does not 
contribute significantly to ATP synthesis, it is believed that parasitic cell death is caused by 
the indirect inhibition of dihydroorotate dehydrogenase, important for pyrimidine 
biosynthesis, which requires the ETC function [65]. 
 
f) Pyrimethamine 
Pyrimethamine is a drug normally used in combination for the treatment of uncomplicated, 
chloroquine-resistant, P. falciparum malaria. It acts as a competitive inhibitor of 
dihydrofolate reductase (DHFR), a key enzyme in the production of tetrahydrofolate, which 
is a cofactor required for DNA and protein synthesis in the parasite [66]. 
 
 
 
 
 
 
 
11 
 
Table 2.4: Targets and structures of some currently used antimalarial drugs. 
Drug Structure Target 
Chloroquine  
 
 
Haemoglobin degradation, 
DNA/RNA synthesis, free 
radical generation [23] 
Quinine 
 
Membrane transport [23] 
Artemisinin  
 
Haemoglobin degradation, 
heme polymerization, free 
radical generation [23] 
Tetracycline   
 
Protein synthesis and DNA 
synthesis [64] 
Atovaquone 
 
Electron transport chain [65] 
Pyrimethamine  
 
Folate mechanism [66] 
 
 
 
12 
 
2.5. Potential targets for novel antimalarial drugs 
 
The spread of multidrug-resistant P. falciparum has emphasised the necessity to develop new, 
affordable and effective antimalarial drugs, for developing countries, where malaria is 
prevalent [23].  Resistance to drugs may be due to defective nucleic acid repair or other 
genomic stability pathways. There have been several important and unrelated parasitic 
biochemical pathways studied in the search for drug target identification. Figure 2.5., below, 
summarizes the biochemical pathways which are potential targets for antimalarial drugs [67].   
 
Figure 2.5: A diagrammatic representation of new molecular drug targets in plasmodium 
species. PVM: Parasitic vacuole membrane; RBCM: Red blood cell membrane; PPM: 
Parasite plasma membrane. 
 
2.6. Traditional medicine 
 
Traditional healers provide alternative health care and treatments that are indigenous to the 
culture and operate outside the government-funded healthcare systems as well as beyond the 
common medical profession practices. They are popular amongst many low to middle-class 
countries [75]. People regularly for maintaining good health [76] and sometimes for both 
chronic and acute diseases normally use traditional medicine, where conventional medicine is 
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inaccessible [77]. Plants have been used as treatment for centuries, and they still serve as a 
base for many pharmaceuticals to date [78]. 
Research on phytochemical compounds has contributed immensely to novel anti-malarial 
drugs. Drugs such as atovaquone; artemisinin and its derivatives; clindamycin; doxycycline; 
tetracycline, are all important examples of the contributions of natural products to the 
development of effective antimalarial drugs [78]. 
 
2.6.1. Medicinal plants used to treat malaria 
 
Medicinal plants are the most popular form of traditional medicine in Africa. Plants are used 
for several ailments like skin disorders, ulcers, diarrhoea, colds, asthma, urinary tract 
infections, malaria, fever, sore throat, diabetes etc. [26]. For generations, numerous medicinal 
plants have been used to combat malaria, each with different mechanisms of action. 
Medicinal plants can be used for one of three characteristics i.e. synergic medicine; support 
of official medicine and Preventive medicine [27]. 
Researchers isolate compounds from medicinal plants, traditionally claimed to cure malaria 
or its symptoms, with the aim of finding a more effective, cheaper and less toxic antimalarial 
drug [28].  
 
2.6.2. Antimalarial phytochemical compounds 
 
One of the groups of compounds that have been explored is sesquiterpenes [29], which are a 
class of terpenes with three isoprene units and have the Molecular formula C15H24. They are 
poisonous to livestock and act as feeding insect deterrents. They also cause allergic contact 
dermatitis in humans [30]. 
Becker et al. used standard phytochemical analysis techniques to isolate a eudesmanolide-
type sesquiterpene lactone, dehydrobrachylaenolide (1); this compound was found to be the 
key active component of Dicoma anomala subsp. gerrardii (Asteraceae) [31]. Compound 1 
showed an in vitro IC50 value of 1.865 μM against a chloroquine-sensitive P. falciparum 
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strain (D10).  Biological activities shown by synthetic derivatives of compound 1 revealed 
that a methylene lactone group should be present in the eudesmanolide for any noteworthy 
anti-malarial activity to occur. This is not the case with artemisinin and thus suggests that 
eudesmanolide-type sesquiterpene lactones use a different mechanism of action from 
artemisinin [31]. 
Wube et al. discovered that the antiprotozoal activity of Warburgia ugandensis 
(Cannelaceae) against P. falciparum and Trypanosoma brucei rhodesiense is due to drimane 
and coloratane sesquiterpenes found in the plant [32]. Compounds isolated from this plant 
include 4(13), 7-coloratadiene-12, 11-olide (2), 11α-hydroxymuzigadiolide (3), muzigadial 
(4), 6α, 9α-dihydroxy-4(13), 7-coloratadiene-11, 12-dial (5), cinnamolide (6), cinnamolide-
3β-acetate (7), mukaadial (8) and ugandensidial (9) [32]. Amongst the discovered 
compounds, Compound 3 was found to be the most active against P. falciparum with an IC50 
value of 6.40µM [32]. 
            
                         
Figure 2.6.2: Compounds isolated from Dicoma anomala (1) and Warburgia ugandensis (2-9) 
[31, 32] 
 
There are several other phytochemical compounds from different classes, which have been 
scientifically proven to possess antimalarial properties. Below is a tabulated summary of 
natural products isolated from medicinal plants, used traditionally to treat malaria [84]. 
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Table 2.6.2: Natural compounds found to possess antiplasmodial activity. 
Medicinal plant Compound name and structure Reference 
Erythrinaabyssinica 
(stem bark) 
 
5-Prenylbutein 
79 
Ficus mucuso (figs) 
 
Mucusisoflavone C 
80 
Lippia javanica 
(leaves and stalks 
 
Dihydroguaiaretic acid 
81 
Helichrysum 
cymosum 
(whole plant) 
 
Helihumulone 
82 
Vernonia 
staehelinoides 
(leaves) 
 
Mucobromic acid 
83 
Vernonia 
staehelinoides 
(leaves)  
Mucochloric acid 
83 
Vernonia 
staehelinoides 
(leaves) 
 
Hirsutinolide 
83 
 
16 
 
2.7. Warburgia salutaris 
 
Warburgia salutaris (G. Bertol.) Chiov. (Canellaceae) is a commonly used medicinal plant 
found in eastern and southern Africa. It is an evergreen tree (Figure 2.6.2), with a fissured 
bark; glossy simple leaves; green flowers and plum-shaped fruits [52], that can grow up to 10 
m in height [33]. The bark and leaves possess antimicrobial activity [37, 53 and 54] and are 
commercially available in a crude form (usually bark) from local muti markets and as over-
the-counter products (containing leaves or leaf extracts) from pharmacies. Warburgia 
salutaris is widely used in traditional medicine to treat coughs, colds, bronchial infections, 
oral thrush, cystitis, malaria and many other ailments [55-59]. 
   
Figure 2.6.3: Bark samples on a traditional market (A) and examples of commercial bark and 
leaf samples (B–E) [60]. Warburgia salutaris tree (F) and flowers (G), taken at the UKZN 
botanical gardens.  
The main compounds which have been isolated from this species include phenols which are 
responsible for its antioxidant effects [34], drimane sesquiterpenoids [35], antimicrobial 
sesquiterpenoid compounds [36, 37] furan and furanones [38]. Although none have been 
reported to possess anti-malarial activity, several drimane sesquiterpenes have been isolated 
from this plant (Table 2.4.1.1).  
 
 
 
 
 
F 
G 
17 
 
Table 2.4.1.1: Compound previously isolated from W. salutaris 
Compound Structure Activity 
Warburganal  
 [39] 
Molluscicidal [40, 41], 
antifungal and antibacterial [42, 
43] activity 
Polygodial 
[44] 
Antifungal and antibacterial 
[42] activity 
Salutarisolide 
[45-57] 
None reported 
Muzigadial 
  [48] 
Antimicrobial and antifungal 
[42, 37] 
Isopolygodial 
 [50] 
None reported 
Mukaadial 
 [45] 
Molluscicidal [45] 
11-hydroxycinnamosmolide 
 [28] 
anti-mycobacterial activity 
[28].   
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2.8. Work scope: 
 
Aim: To validate the use of W. salutaris in traditional medicine against malaria.  
 
Objectives: 
 To collect the plant material and prepare a voucher specimen. 
 To isolate, purify and characterize active phytochemical compound(s) from the plant 
using chromatographic and spectroscopic techniques. 
 To examine the in vitro antiplasmodial activity of the isolated compound(s) crude 
plant extract. 
 To determine the in vivo antiplasmodial activity of the crude extracts and isolated 
compound(s). 
 To investigate the cytotoxicity of the active compound(s) 
 To carry out in silico studies on the active compound(s) 
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Chapter Three 
Materials and methods 
 
This chapter includes a brief description of all methods carried out in this study as well as a 
list of all important chemicals, reagents and equipment used in this study. Details of the 
preparation of reagents and the details of the methodology are in Appendix 1 and 2, 
respectively. 
3.1. Materials  
3.1.1. Chemicals 
 
Unless otherwise stated, all chemicals and solvents used were of analytical grade from Merck 
chemicals (PTY) LTD, South Africa (SA). Chloroquine, artesunate, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT salt), fetal bovine serum, penicillin, streptomycin, 
eagles minimum essential medium (EMEM) tween 20, dimethyl sulphoxide (DMSO), 
Giemsa  DNA, isoform, silica gel (60: 0.063-0.200mm), sea sand (purified by acid and 
calcined for analysis), TLC Silica gel 60 F254 20x20 cm Aluminium sheet, human embryonic 
kidney (HEK293) cells (Anti-viral Gene Therapy Unit, Medical School, University of the 
Witwatersrand, SA,), liver hepatocellular carcinoma (HepG2) cells (Highveld Biologicals 
(Pty) Ltd, Kelvin, SA).  
 
Other materials and methods include: 
Grinder- Hippo Mills (AC Trading) 
Rotary evaporator- Heidolph Instruments GmbH & Co. Germany 
UV Light- SPECTROLINE CL-150 Ultraviolet Fluorescence Analysis Cabinet 
Nuclear Magnetic Resonance-Burker (Polychem suppliers) 
Centrifuge- Eppendorf (Merck) 
Sprague Dawley rats-Biomedical research unit, University of KwaZulu-Natal 
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3.2. Methodology (Appendix 2 for details) 
3.2.1. Plant material  
 
Fresh stem bark of Warburgia salutaris was collected from the University of KwaZulu-Natal, 
Pietermaritzburg campus, Botanical gardens (29° 37′ 30′′ S, 30° 24′ 14′′ E) in March 2016. 
The plant was identified by the UKZN botanical gardens horticulturist, Mrs Alison Young. A 
voucher specimen was prepared and stored at the University of KwaZulu-Natal 
Pietermaritzburg Herbarium, voucher number: NU0043932. The stem bark was air-dried, 
ground into powder and stored in sterile brown bottles until needed. 
3.2.2. Extraction crude extract 
 
The plant material (4.2 kg) was sequentially extracted (1:5 w/v) with dichloromethane 
(DCM), chloroform, ethyl acetate and methanol. Extracts were filtered through a Whatman 
(No. 1) filter paper; the residue was air dried and the extract concentrated using a rotary 
evaporator. The rotary evaporator ran at a reduced pressure with different temperatures per 
solvent i.e. DCM-45
o
C; chloroform 61
o
C; ethyl acetate-77
o
C, and methanol-65
o
C.   
The concentrated extracts were dried overnight. The DCM extract weighed 85 grams; ethyl 
acetate extract=3.7 grams; chloroform extract=3.8 grams; and the methanol 
extract=83.3grams. 
 
3.2.3. Isolation of pure compound 
 
Column chromatography was done for the isolation of natural compounds from the DCM 
extract, Merck silica gel (60: 0.063-0.200mm) was used as the stationary phase, and Hexane: 
ethyl acetate ratio as the mobile phase. Hexane and ethyl acetate was distilled, at 67
o
C and 
77
o
C respectively, prior to use in the column. The solvent ratios were from 9Hex:1Ethyl ac. to 
2Hex:8Ethyl ac., 10 grams of the extract was used with 30x grams of silica gel, per column.  
 
21 
 
Thin layer chromatography was used to check the presence of a compound at each ratio, a 
20% sulphuric acid in methanol solution was used to fix the TLC plates; they were then 
viewed under UV light. Fractions were collected per 80ml and combined according to their 
TLC profiles.  At the ratio 8Hex:2 Ethyl ac. A single bright spot appeared on the TLC plate when 
viewed under UV light, with a Retardation Factor (RF) value of 0.6.  
The combined fractions were dried in the fume hood overnight, fractions from the 8Hex:2 Ethyl 
ac., ratio dried into 6 grams of a white amorphous powder (NN-01), with a stinging effect to 
the nostrils.  
 
Figure 3.1: TLC plate showing compound present in the crude extract and the isolated 
compound. 
 
3.2.4. Structural elucidation 
 
The structure of compound NN-01 was determined using Nuclear magnetic resonance 
(NMR) techniques (
1
H, 
13
C, COSY, DEPT, NOESY, HMBC and, HSQC), infrared (IR) 
spectra and X-ray crystallography. The NMR data was collected using Filezilla 3.21.0 
copyright © 2004-2016 Tim Kosse and processed, into spectra, using Spinworks 4.0 
copyright ©2014, Kirk Marat, University of Manitoba to give the NMR spectrum.    
The structure of compound NN-01 was determined through the study of the chemical shifts 
(table 3.1) and spectra, (Appendix 3). NN-01 was identified as, a new compound, Mukaadial 
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acetate (Figure 3.1). It was the first time Mukaadial Acetate was isolated from this plant or 
any higher plant species. Figure 3.2 below shows the single mass spectra of Mukaadial 
Acetate. 
Table 3.1: Proton (
1
H) and carbon 13 (
13C) NMR chemical shifts (δ, ppm) of M. Acetate 
Position δc (ppm) CHn δH (ppm) 
1 66.13 CH 5.91(t, H, J = 4.8 Hz) 
2 148.60 CH 7.01(d, H, J = 4.8 Hz) 
3 141.00 C  
4 32.56 CH 4.07 
5 41.66 C  
6 31.83 CH2  
7 17.70 CH2  
8 44.02 CH2  
9 34.00 C  
10 44.97 CH 2.06(d, H, J = 4.8 Hz) 
11 193.01 CHO 9.76 
12 201.44 CHO 9.48 
13 19.95 CH3 1.34 
14 24.75 CH3 1.17 
15 21.44 CH3 1.03 
16 170.01 COOR  
17 19.95 CH3 2.14 
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Figure 3.2: X-ray structure of Mukaadial Acetate (C17H24O4; 292 g/mol) 
  
 
 Figure 3.3: Single mass analysis of Mukaadial Acetate 
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3.3. Section A 
3.3.1. Cytotoxicity MTT assay 
 
The University of the Witwatersrand, Medical school, Antiviral Gene Therapy Unit, SA 
provided the HEK293 (Human embryonic kidney) cells, while the HepG2 (liver 
hepatocellular carcinoma) cells were obtained from the Highveld Biologicals (Pty) Ltd, 
Kelvin, SA. The assay method was a modification of that described by Mosman (1983)[40], 
it is used to calculate the cells’ metabolic activity, via reducing MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) into formazan salt by the enzyme succinate-
tetrazolium reductase within the cell. The cells were developed to semiconfluent in the flasks 
for tissue culture (25 cm
2
) in Eagle's minimal essential medium containing 100 U/ml
 
penicillin, 100 μg/ml streptomycin as well as fetal bovine serum (10%). Cells were then 
prepared to a density of 21 x 10
3 
cells in each well, with medium (100 µl) in a 96 well plate. 
A 24 hour incubation (37°C; 5% CO2) followed, the old medium was then removed, while 
fresh medium (100 µl) was added. Varying (50µg/ml, 100µg/ml and 150µg/ml) of the 
compound in triplicates were added onto the cells and were then further incubated (48 hours; 
37°C). Cells without the experimental compound were used as the positive controls which 
will show viability at 100%.  
The original medium was removed, after 48 hours of incubation and 100 µl new medium as 
well as 5 mg/ml MTT in PBS added. This went into incubation (37
o
C) for another 4 hours. 
MTT and medium were then discarded, and 200 µl of DMSO was added per well, for 
dissolving the formazan. The absorbance of resulting mixture was then read with a Mindray 
96A micro plate reader (Vacutec, Hamburg, Germany). A wavelength of 570 nm (detection 
λ) was used and that of 630 nm as the reference wavelength of nonspecific signals. The 
percentage viability of the cell was linked to absorbance and worked out in reference to the 
positive control using the equation: [(OD570 Treated)/ (Control)] x 100. All experimentations 
were done in triplicates.  
3.3.2. In vitro antiplasmodial activity 
 
The in vitro antiplasmodial activity was carried out at the University of Cape Town, Division 
of Pharmacology, South Africa. The test samples were tested in triplicate on one occasion 
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against chloroquine-sensitive (CQS) strain of Plasmodium falciparum (NF54). Continuous in 
vitro cultures of asexual erythrocyte stages of P. falciparum were maintained using a 
modified method of Trager and Jensen (1976) [87]. Quantitative assessment of 
antiplasmodial activity in vitro was determined via the parasite lactate dehydrogenase assay 
using a modified method described by Makler (1993) [88]. 
The test samples were prepared to a 20 mg/ml stock solution in 100% DMSO. Samples were 
tested as a suspension if not completely dissolved. Stock solutions were stored at -20ºC. 
Further dilutions were prepared on the day of the experiment. Chloroquine (CQ) and 
artesunate were used as the reference drugs in all experiments. A full dose-response was 
performed for all compounds to determine the concentration inhibiting 50% of parasite 
growth (IC50–value). Test samples were tested at a starting concentration of 100 μg/ml, which 
was then serially diluted 2-fold in complete medium to give 10 concentrations; with the 
lowest concentration being 0.2 μg/ml. The same dilution technique was used for all samples. 
Reference drugs were tested at a starting concentration of 1000 ng/ml. The highest 
concentration of solvent to which the parasites were exposed to had no measurable effect on 
the parasite viability (data not shown). The IC50-values were obtained using a non-linear 
dose-response curve fitting analysis via Graph Pad Prism v.4.0 software. 
3.3.3. Molecular Docking 
The crystal structure of PfHGXPRT in complex with hypoxanthine (PDB: 3OZF) [89] was 
retrieved from the Protein Data Bank. This protein structure exists as a tetramer, therefore, 
chain A was selected to reduce computational cost. Protein structure and ligand modifications 
were conducted in UCSF Chimera [90] in preparation for docking. M. acetate docking into 
the PfHGXPRT binding site was conducted using AutoDock Vina [91]. Non-polar 
hydrogen’s, Geister charges, possible torsional degrees of motion and rotatable bonds of M. 
acetate, as well as Kollman charges [91] for all atom types, were assigned in AutoDock Tools 
interface. The Lamarckian Genetic Algorithm [92] was applied to generate a docked 
conformation. M. acetate was docked using a grid box size of 66×64×54 Å which was 
generated to encapsulate the active site amino acid residues of the PfHGXPRT structure. 
Coordinates of a docked M. acetate-PfHGXPRT complex were saved for further molecular 
analyses conducted in UCSF Chimera and LigPlot [94].  
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3.4. Animal Experiment 
 
3.4.1. Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-Natal Ethics committee 
(reference: AREC/053/016, appendix 4)  
3.4.2. Animals 
Male Sprague-Dawley rats, 16-18 weeks old (80-120 g) bred and housed at the University of 
KwaZulu-Natal, Westville campus, Biomedical Resource Unit were used in this study. The 
animals were maintained under standard laboratory conditions. The rats had free access to 
food and water. 
3.4.3. Preparation of drugs and extract 
Concentrations 0.5 mg/kg; 2.5 mg/kg and 5 mg/kg were prepared by dissolving the 
Mukaadial Acetate or crude extract in tween 20 and distilled H2O was added to the required 
volume. For the main study, 1.5mg/kg of the crude extract and Mukaadial Acetate was 
prepared and 60 mg/kg of chloroquine was prepared, in the same way, for the control group. 
The drugs were administered via oral gavage.  
3.4.4. Induction of malaria 
Malaria was induced by a single intra-peritoneal injection of 10
5 
Plasmodium berghei 
parasitized RBC [9]. The rodent CQ sensitive P. berghei parasite was obtained from Prof. 
Peter Smith (University of Cape Town, Division of Clinical Pharmacology, South Africa). 
Successful malaria infection was confirmed by microscopic examination of Giemsa stained 
thin blood smears, from the rat tail. Percentage parasitemia greater than or equal to 20% was 
considered as stable malaria state before commencing with experimental procedures.   
3.4.5. Experimental design  
 
Acute studies were carried out to determine whether proposed concentrations of the Crude 
extract and Mukaadial Acetate would have any adverse effects on the animals. Four male 
Sprague Dawley rats were treated with two different Mukaadial Acetate and extract 
concentrations (0.5 mg/kg and 5 mg/kg) for five consecutive (n=1/group). The rodents were 
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closely monitored during the course of the treatment period and for five consecutive days 
post-treatment. The experimental animals were then sacrificed on day ten and blood was 
collected for a haematology profile. 
 
Following the acute study, a 21-day experimental pilot study was conducted to investigate 
the antiplasmodial efficacy of selected extract and Mukaadial Acetate concentrations (0.5; 
2.5; and 5 mg/kg). Malaria induction was done on day 0 of the experimental study using 10
5
 
P. berghei infected RBCs on Sprague-Dawley rats. The experimental study was divided into 
pre-treatment (day 0-7), treatment (day 8-12) and post-treatment period (day 13-21) 
Percentage parasitemia determination using Giemsa stained thin film blood smears was done 
daily post-P. berghei infection. On day 21, all the animals were sacrificed by isoform 
inhalation. Blood was collected by cardiac puncture into EDTA tubes for haematology 
parameters measurement, as shown in the schematic diagram below (Figure 3.4.1). 
Pilot study animal design: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.1: Schematic diagram of pilot study animal design. 
18 Male Sprague-Dawley rats (80-120g) 
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Day 0-Day 7 
Treatment Period 
Day 8-Day 12 
Post-Treatment Period 
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Survival profile 
Haematology profile 
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3.4.5.3. Main study 
 
Forty-eight male Sprague Dawley rats (80-120g) were randomly divided into two major groups: 
non-P. berghei infected and P. berghei infected (infected with 10
5
 Plasmodium berghei 
parasitized erythrocytes, intra-peritoneally (i.p.) on day zero) (n=6/group). 
Treatment commenced on day 8 of the study. The non-infected group had two sub-groups 
(n=6/group), receiving oral dosing of 2.5mg/kg crude extract and 2.5mg/kg Mukaadial Acetate 
each. The infected group had six sub groups (n=6/group): absolute control-vehicle; positive 
control-CQ (day 8-11); crude extract x5
#
-2.5 mg/kg (day8-12); M. acetatex5
#
-2.5mg/kg (day8-
12);; Crude extract x1*-2.5 mg/kg (day8); M. acetatex1*-2.5 mg/kg (day8). The animals were 
then monitored for 9-13 days (varies per group) after the last day of treatment, until day 21. *x1-
treated for one day; 
#
x5-treated for five days 
Main study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.2: Schematic diagram of main study animal design  
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Percentage parasitemia was determined by thin blood smears prepared from the tail blood of each 
rat, fixed with methanol and stained with 20 % Giemsa every day from day 3 to day 21. The 
animals were sacrificed on day 21 and determination of, haematology profile and survival profile 
was done. 
The body weights of the rats were monitored to observe whether the isolated compound prevents 
weight loss that is commonly observed with increasing parasitemia in infected rats. Weights were 
taken at 3-day intervals until day 21. 
The rat grimace scale [10], from the National Centre for the Replacement Refinement and 
Reduction of Animals in Research (NC3Rs), was used to ensure animal welfare was observed 
during the experiment. Orbital tightening; nose and cheek flattening; ear change; and whisker 
change was used as parameters for the grimace scale.  
 
3.5. Calculating parasitemia 
 
The parasitemia level was determined by counting the number of parasitized erythrocytes out of a 
hundred RBC in five random fields of the microscope. Average percent parasitemia was 
calculated by using the formula below [11, 12]. 
 
 
% Parasitemia  
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3.6. Statistical analysis  
 
Data was analysed using two-way analysis of variance and group statistics, followed by 
Benferroni post hoc test. The mean ± SEM was calculated. The 2010 Microsoft Excel 
Program and version.4.0 Graph Pad Prism software (Graph Pad Prism, Inc.: San Diego, CA, 
USA, 1994–2003) were used for the statistical analysis of differences amongst the mean 
values calculated for the different trial groups, for IC50. P values ≤0.05 were taken as 
significant. 
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Chapter Four 
Results 
4.1. Section A 
4.1.2. Anti-plasmodial and cytotoxic activity 
The bioassay separation of the DCM crude extract of W. salutaris led to the isolation and 
characterization of Mukaadial acetate. This was the first time that this compound was isolated 
from this plant, and it is the first time its antimalarial activity is being reported. The observed 
antimalarial and cytotoxic activity are depicted in table 4.1. The DCM extract showed higher 
activity than the methanol and hexane extracts. 
 
Sample code *IC50 (µg/ml)         Cytotoxicity (µg/ml) 
 HEK293 HEPG2 
W. salutaris (DCM)       0.01±0.30     
W. salutaris  
(Methanol) 
 11.32±61 36.7 ± 0.8 119.2 ± 8.8 
W. salutaris 
(Hexane)  
167.91±08
#
   
M. acetate 0.44±0.10   
CQ 4.9±0.07
#
   
Art <2
#
   
 
 
4.1.2. Active Site Analysis 
Molecular docking is an indispensable tool in molecular biology and computer-aided drug 
design as it predicts the binding modes of a ligand to a 3D structure of a target. It was 
appropriate therefore that the molecular docking of M. acetate be studied with its target 
protein. The active site of the PfHGXPRT is subdivided into four functional regions namely; 
Table 4.1. In vitro anti-plasmodial and cytotoxic activity of M. acetate 
*IC50: Inhibitory concentration; 
#
=ng/ml 
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the purine, the phosphate, the ribose and the magnesium ion-pyrophosphate binding site [93]. 
Amino acid residues predominantly forming a purine binding site include; Ile146, Asp145, 
Phe197, Leu 203, Lys176 and Val198 [93]. The phosphate binding site comprises Tyr116, 
Asp148, Thr149, Gly150 and Thr152 [93]. The magnesium-pyrophosphate binding site is 
primarily composed by residues Lys77, Gly78, Arg112, Ser115, Tyr116, Arg210 [93].  
  
 
Figure 4.1: Representation of the 3D structure of PfHGXPRT protein with mukaadial acetate 
(green) bound to the active site. 
4.1.3. Mukaadial acetate Binding Mode  
 
It was determined that M. acetate binds to the pyrophosphate and ribose binding sites of 
PfHGXPRT protein with a docking score of -5.9 kcal/mol. The predicted binding mode of M. 
acetate o PfHGXPRT binding site and interactions with residues inhabiting the binding site 
are depicted in Figure 4.2. The generated intermolecular interactions between M. acetate and 
binding site residues were predicted to include hydrogen bonding and hydrophobic 
interactions. Four hydrogen bond interactions were formed in the binding site: two between 
the third oxygen (O3) of M. acetate and Arg210 amide group atoms (NH1 and NH2); another 
two between the fourth oxygen atom (O4) of M. acetate and Arg112 amide group (NH2) and 
Lys114 amide group (NZ). 
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Figure 4.2: Predicted binding modes of M. acetate in 3D (A) [94] and generated 
intermolecular interactions (B) [95] within the PfHGXPRT binding pocket.   
 
  
34 
 
 
4.2. Section B 
4.2.1. Acute study results and observations 
An acute toxicity study is done to determine the adverse effects of a substance from multiple 
exposure in a short period of time [110]. The study was carried out in accordance to with the 
OECD guidline 423 [110], using concentrations of 0.5, 1.5 and 2.5 mg/kg. 
The animals showed no negative behavioural changes in all experimental groups, as they 
remained active and no adverse effects were observed.  
4.2.2. Pilot study results and observations 
 
The pilot study results showed increased antiplasmodial effect of both the W. salutaris crude 
extract and M. acetate, in comparison to the control. All the selected doses had no negative 
haematology effects on the experimental animals. These results lead to further studies (main 
study) using the lowest active concentration with a difference in dosing. 
4.2.2.1. Effects of W. salutaris and mukaadial acetate on  percentage parasitemia  
 
W. salutaris and M. acetate, reduced % parasitemia in a dose-dependent manner, in comparison 
to control, though the differences between the W. Salutaris and M. acetate were not statistically 
significant as Figure 4.3. Peak % parasitemia was on days 7-8 post P berghei infection.  
Following the first day of treatment (day8), there was a decrease in % parasitemia, which 
gradually continued to decrease until day 21 of the experimental study for all the experimental 
groups. 
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Figure 4.3: Percentage parasitemia of Plasmodium berghei infected SD rats treated with 
Warburgia salutaris and M. acetate. Where IMA-O.5: Infected mukaadial acetate treated 0.5 
mg/kg; IMA-2.5: Infected mukaadial acetate treated 2.5 mg/kg; IMA-5: Infected mukaadial 
treated 5 mg/kg; ICE-0.5: Infected crude extract treated 0.5 mg/kg; ICE-2.5: Infected crude 
extract 2.5 mg/kg; ICE-5: Infected crude extract 5 mg/kg and IC: Infected control. 
  
Pre-treatment Treatment Post-treatment 
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4.2.2.2.Haematology results 
 
All the haematology parameters were within the respective reference ranges, for all the 
experimental groups as shown in Table 4.2 below. Indicating that the chosen compound and 
crude extracts have no adverse effects on the animals blood parameters. Values are presented as 
means (n=3 for each group). IMA-0.5:0.5mg/kg M. acetate treated; IMA-2.5:2,5mg/kg M. acetate 
treated; IMA-5:5mg/kg M. acetate treated; ICE-05:05mg/kg W. salutaris crude extract treated; 
ICE-2.5:2.5mg/kg W. salutaris treated; ICE-5:5mg/kg W. salutaris treated. Levels of 
significance, *P<0.05, ** P<0.01, *** P<0.001 in comparison to control group. 
Table 4.2: Haematology parameters post Plasmodium berghei infection, treated with Warburgia 
salutaris and mukaadial acetate. 
Groups Haematology parameters 
WBC 
(10
3
/µl) 
RBC 
(10
6
/µl) 
HGB 
(g/dL) 
HCT 
(%) NE (%) LY (%) MO (%) EO (%) BA (%) 
IMA-
0.5 4.93 8.10 14.97 42.67 17.73 67.07 13.40 0.93 0.87 
IMA-
2.5 4.60 8.26 15.73 44.67 14.20 72.40 14.17 1.40 0.77 
IMA-5 
6.03 8.14 14.93 42.97 19.60 56.70 16.90 1.60 0.40 
ICE-
0.5 6.73 7.74 13.53 39.26 13.23 72.87 14.73 1.27 0.30 
ICE-
2.5 5.70 7.82 14.07 40.73 10.00 78.13 11.33 0.20 0.33 
ICE-5 
7.00 8.01 14.37 42.00 17.73 68.73 17.03 0.20 0.50 
 
  
37 
 
4.2.3. Main animal study results 
 
The study results showed varied antiplasmodial activity with the five-day treatment groups 
showing increased antiplasmodial effects than those of the one-day treatment. The selected 
dose had no negative haematology effects on the experimental animals. 
4.2.3.1. Effects of W. salutaris and Mukaadial acetate on percentage parasitemia  
Percentage parasitemia data is shown in table 4.3 below. Values are presented as means. Where 
UMA-Uninfected M. acetate treated; UCE-Uninfected crude extract treated; IC-infected without 
treatment; ICQ-infected chloroquine treated; ICE1-infected crude extract 1-day treatment; ICE2-
infected crude extract 5-day treatment; IMA1-infected M. acetate 1-day treatment; IMA2-
infected M. acetate 5-day treatment.  
Levels of significance, *P<0.05, ** P<0.01, *** P<0.001 in comparison to control group. 
 
Table 4.3: Percentage parasitemia Plasmodium berghei infected SD rats infected treated with 
Warburgia salutaris and mukaadial acetate. 
Groups Percentage parasitemia 
Day 
3 
Day 
5 Day 7 Day 9 Day 11 Day 13 Day 15 
Day 17 Day 19 Day 21 
IC 
9.20 12.97 18.20 39.70 52.37 52.20 43.13 
 
35.77 
     
28.30 
 
25.27 
ICQ 
7.70 12.00 17.77 33.60 22.77*** 13.23*** 9.30*** 
 
6.67*** 
 
4.67*** 
 
0.53*** 
ICE1 
6.87 10.20 27.23** 39.47 26.53*** 20.00*** 20.96*** 
 
25.97*** 
 
27.87 
 
25.27 
ICE2 
8.40 17.50 28.07*** 39.90 25.13*** 16.13*** 10.90*** 
 
7.03*** 
 
4.30*** 
 
1.40*** 
IMA1 
6.27 15.63 29.20*** 43.37 25.97*** 23.57*** 21.27*** 
 
24.5*** 
 
26.13*** 
 
28.87*** 
IMA2 
4.97 12.17 22.43 33.03* 21.70*** 14.57*** 8.90*** 
 
5.90*** 
 
3.87*** 
 
0.70*** 
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4.2.3.2. Effects of W. salutaris and Mukaadial acetate on haematology profile. 
The table below represents haematology parameters. The study groups are represented as, UMA-
Uninfected M. acetate treated; UCE-Uninfected crude extract treated; IC-infected without 
treatment; ICQ-infected chloroquine treated; ICE1-infected crude extract 1-day treatment; ICE2-
infected crude extract 5-day treatment; IMA1-infected M. acetate 1-day treatment; IMA2-
infected M. acetate 5-day treatment. ). Levels of significance, *P<0.05, ** P<0.01, *** P<0.001 
in comparison to control group. 
 
Table 4.4: Haematology profile of study groups post Plasmodium berghei infection treated 
with Warburgia salutaris and mukaadial acetate.  
 
Groups Haematology parameters 
WBC 
(10
3
/µl) 
RBC 
(10
6
/µl) 
HGB 
(g/dL) 
HCT 
(%) NE (%) LY (%) 
MO 
(%) EO (%) BA (%) 
UMA 
6.52 2.69 14.47 17.05 33.23 53.18 2.32 9.20 2.07 
UCE 
8.67 3.43 14.88 20.45 26.83 59.27 2.78 9.18 1.93 
IC 
8.35 *3.25 13.35 18.35 27.32 52.07 3.73 13.70 3.18 
ICQ 
15.02 3.99 12.48 21.88 21.67 57.82 2.18 7.98 ***11.15 
ICE1 
2.45 1.26 15.25 8.95 23.48 51.57 3.82 10.98 10.15 
ICE2 
4.05 2.77 14.02 16.43 18.50 61.43 2.38 8.12 9.57 
IMA1 
2.23 2.93 13.05 16.50 18.72 62.42 2.85 7.67 8.35 
IMA2 
2.38 2.23 13.63 12.90 27.25 50.93 2.73 9.32 9.72 
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4.2.3.3. Effects of W. salutaris and Mukaadial acetate on animal weight. 
 
The difference in weight was measured at two-day intervals to determine whether the W. 
salutaris crude extract and M. acetate prevent weight loss, commonly observed in malaria. 
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Figure 4.4: Difference in weight of Plasmodium berghei infected SD rats, treated with Warburgia 
salutaris and M. acetate over a 21-day period. Values are presented as mean ±SEM. UMA-
Uninfected M. acetate treated; UCE-Uninfected crude extract treated; IC-infected without 
treatment; ICQ-infected chloroquine treated; ICE1-infected crude extract 1-day treatment; ICE2-
infected crude extract 5-day treatment; IMA1-infected M. acetate 1-day treatment; IMA2-
infected M. acetate 5-day treatment. Two-way analysis of variance was carried out for all 
percentage parasitemia data.  
Levels of significance, *P<0.05, ** P<0.01, *** P<0.001 in comparison to control group. 
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Chapter Five 
Discussion 
5.1. Anti-plasmodial and Cytotoxic activity 
 
Most people, living in malaria endemic areas, do not to afford antimalarial drugs, and thus 
rely on medicinal plants as primary treatment for malaria [97]. Discovering novel compounds 
of plant origin, which may be used in drug development, is still the main goal of ethno 
pharmacology [98]. In order for a drug to be considered effective, it should have an IC50 
≤1µg/ml and a selectivity index that is at least ten times more active on the parasite than it is 
on human cell-lines [99]. Mukaadial Acetate conforms to these standards. The W. salutaris 
DCM (0.1±0.03 µg/ml) extract showed greater activity than the methanol (11.32±61 µg/ml) 
and hexane (167±0.8 µg/ml) extracts. Therefore, the DCM extract was further purified to 
isolate the active compound, M. acetate (0.44±0.10 µg/ml), which also showed in vitro 
antimalarial activity and was later used with the DCM extract on in vivo experiments. 
Previous studies have shown extracts and isolated compounds with great antiplasmodial 
activity and toxicity values, such as; the methanol fraction of Clerodendrum myricoides 
leaves, an Ethiopian medicinal plant which was proven to have good antimalarial properties 
with an IC50 of 16.8 ± 2.65 μg/ml [107]. Myristic acid and β-caryophyllene, purified 
compounds, from Murraya Koenigii, were also found to be very active with IC50 values of 
10.5 ± 0.8 and 8.25 ± 0.2 μg/mL, respectively [108]. However, the current study shows 
greater activity and lower cytotoxic effects of the DCM extract and its isolated compound M. 
acetate.  
Literature shows that there has been no report of any other isolated antimalarial compound 
from W. salutaris. According to Katiyar, et al. (2012), natural sources hold a promise of 
delivering natural compounds as candidates or as a base for synthetic analogues to overcome 
any limitations of the natural compound in drug discovery [100]. The appreciable 
antiplasmodial activity of M. acetate makes it eligible for structural modification studies to 
reduce cytotoxicity while retaining or improving antiplasmodial activity. Based on the 
literature there have been no reports on M. acetate. 
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5.2. In vivo Anti-plasmodial efficacy 
 
The rodent parasite P. berghei has been proven as the best in the early investigation of 
antimalarial activity of new test compounds [101]. Compounds that increase the survival time 
of rodents [102] and have more than 30% parasite inhibition [103] in comparison to the 
absolute control group are considered effective in standard screening tests, which is in 
agreement with the findings of this study as shown in Figures 4.13-4.16. M. acetate and W. 
salutaris showed dose-dependent parasite reduction in the pilot study, and optimum parasite 
inhibition is observed in the main study, five-day treatment groups, for both M. acetate and 
W. salutaris. 
Gebretsadik and Mekonnen reported the C. myricodies ethyl acetate and methanol extracts to 
have 77.24% and 65.21% suppressive effects on P. berghei infection in mice at 300mg/kg 
doses [107].The root extract of Echinops kebericho, an Ethiopian medicinal plant was 
reported to have 57.29±1.76% parasite suppression at 500mg/kg on a chloroquine (CQ) 
sensitive P. berghei strain [109]. In vivo studies of the M. koenigii leaf crude ethyl acetate 
extract (600mg/kg) showed a 86.6% P. berghei malaria parasite reduction in mice. The two 
purified compounds of this extract, myristic acid and β-caryophyllene, were found to 
significantly reduce parasitemia by 82.6 and 88.2 % at 100mg/kg/body weight [108]. 
Although these extracts and compounds function by reducing infection in the blood stage as 
observed in the current study, the W. salutaris DCM extract and M. acetate possess higher 
affinity for the parasite with suppression values of 94.46 and 97.2%, respectively, at a 
significantly lower dosage of 1.5mg/kg. Therefore, the current study results supersede most 
of those reported in literature.  
Effective anti-plasmodial products are expected to have protective effects against the loss of 
weight commonly observed in malaria infection [104]. In this study, these protective effects 
were observed in the M. acetate and W. salutaris groups as shown in Figure 4.26. 
Furthermore, the significant suppression of parasitemia at 1.5mg/kg for both the W. salutaris 
crude extract and M. acetate confirms that this plant has antimalarial effects in the late stages 
of P. berghei infection.  
Although not significant, the difference in activity between M. acetate and W. salutaris crude 
extract may be justified by the presence of other secondary metabolites in the impure crude 
extract that do not possess antimalarial activity and may, therefore, have complex 
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biochemical effects contributing to slightly reduced therapeutic effects when compared to the 
pure M. acetate. 
Low red blood cell count and reduced haematocrit in malaria infection are consistent with 
previous severe malarial anaemia studies [104]. Evans et al (2006) showed that the decrease 
in RBC production and RBC destruction in response to parasite invasion may indirectly lead 
to haematocrit and haemoglobin levels in the blood of infected animals [104]. CQ treatment 
also reduced haematocrit levels, which is supported by previous reports, that suggest that the 
binding of CQ to infected RBC leading to the eventual destruction of the parasite along with 
the RBC, has anaemic effects [105]. However, the mechanisms by which haematology 
parameters were affected are not described in this study. The measurement of plasma 
chemokine and cytokines may provide mechanisms by which observed malaria-induced 
haematology changes occurred. 
Substances with antioxidant activity have antimicrobial activity, associated with elevated 
oxidative stress upon infection [106]. Previous studies have confirmed antioxidant activity of 
this plant [34], which may explain reported anti-microbial and antifungal [43,42] and anti-
malarial activity. 
5.3. Mukaadial acetate Binding activity 
 
An interaction between M. acetate O3 and Gly78 nitrogen atom was observed and is 
attributed to steric forces generated between the two atoms. M. acetate also formed 
hydrophobic interactions with residue Leu76, Lys77, Val113, Ser115, Tyr116, Glu144, 
Asp145, Ile146, Phe197 and Asp204. The observed interactions involved hydrophobic 
residues known to participate in purine binding (Tyr116, Ile146 and Phe197) [96], 
pyrophosphate and ribose binding (Tyr116, Ser115, Glu144, Tyr116, Asp204, Arg210, 
Arg112, Lys77, Gly78 and Asp145) [93] thus implying that M. acetate fitted in the active site 
with an optimum conformation.  
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Chapter Six 
Conclusion 
 
The target for this study was to scientifically validate the use of W. salutaris in Zulu 
traditional medicine. Results obtained show that W. salutaris possesses antimalarial activity, 
the active compound found to be M. acetate, which shows appreciable inhibition of parasite 
growth. 
Molecular docking revealed that the isolated compound effectively binds to the active site of 
the parasite, forming respective hydrogen bonds, steric and hydrophobic interactions which 
largely contribute to its binding affinity. 
The in vivo antiplasmodial studies with chloroquine-sensitive P. berghei show that W. 
salutaris has very good anti-malarial activity and protective effects on the survival of 
malaria-infected rodents.  
Mukaadial acetate could serve as a lead compound for the development of a relatively potent 
drug in the treatment of malaria. However, more studies are required to determine the 
compound’s mechanism of action on other in vitro and in vivo models. The results obtained 
support the use of W. salutaris in traditional medicine, to treat malaria. 
6.1. Suggestion for future studies  
The future direction for the current study would be the measurement of plasma chemokine’s 
and cytokines to clarify the mechanism on blood parameters. Determination of the 
bioavailability of M. acetate using different modes of drug administration. Histological 
analysis of the harvested organs may give information regarding possible adverse effects of 
M. acetate on animal organs. The production and analysis of the bioactivity M. acetate 
chemical derivatives may lead to compounds with greater activity. 
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Appendix 1 
Preparation of reagents 
1.1  20% sulphuric acid 
20ml of sulphuric was prepared in 80ml methanol 
1.2 Phosphate buffered saline (for infection) 
8g of sodium chloride, 0.2g of potassium chloride, 0.24g of potassium dihydrogen phosphate 
and 1.44g of disodium hydrogen phosphate were prepared into 800ml of distilled water,  the  
pH was adjusted to 7.4 with HCl and distilled water was added to a volume of 1litre.  
1.3 Phosphate buffered saline (for Giemsa staining) 
0.7g of anhydrous potassium dihydrogen phosphate and 1.0g disodium hydrogen phosphate 
was prepared in 800ml of distilled water, the pH was adjusted to 6.8 and distilled water was 
added to a volume of 1 litre. 
1.4 Giemsa stain 
Concentrated Giemsa was diluted to 20% in the PBS Giemsa stain buffer. 
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Appendix 2 
Details of methodology 
2.1 Packing the column 
The column was packed with cotton at the base; hexane was added to allow a thin line of 
Merck; which was followed by silica gel (300grams), mixed with solvent to ensure no 
bubbles were formed; another thin sea sand layer was added and finally 10 grams of the 
DCM crude extract. 
2.2. Structural studies 
2.2.1. Nuclear magnetic resonance 
 
NMR studies are done in order to determine the structure of organic molecules, in this study, 
the white amorphous powder obtained from the column, was sent to an NMR specialist Mr 
Craig Grimmer, at the UKZN-Pmb campus Chemistry department.  The techniques carried 
out were 
1
H NMR; 
13
C NMR; DEPT; COSY; NOESY; HSQC; and HMBC. The NMR data 
was collected using Filezilla 3.21.0 copyright © 2004-2016 Tim Kosse and processed, into 
spectra, using Spinworks 4.0 copyright ©2014, Kirk Marat, Univeristy of Manitoba to give 
the NMR spectrum. 
2.2.2. Mass spectroscopy 
 
Low resolution and high resolution mass spectroscopy was done at the UKZN-Pmb campus 
Chemistry department. MS measures the masses of atoms within a sample. 
2.2.3. Infrared spectroscopy 
 
IR is used to determine functional groups in molecules by measuring the vibrations of atoms. 
Stronger bonds and light atoms generally vibrate at a high stretching frequency. 
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2.3. Molecular Docking 
 
It is a tool used, in structural molecular biology and computer-assisted drug design, to predict 
the predominant binding mode/s of a ligand with a protein of known three-dimensional 
structure. 
 
3.4. X-ray crystallography 
 
This a tool used to identify the atomic and molecular structure of a crystal. The measure of 
angels and intensities of beams is used to produce a three-dimensional picture of the density 
of electrons within the crystal. The compound was recrystallized using hexane i.e. it was 
boiled in hexane for 5-10 minutes, then left to evaporate at room temperature until just the 
crystals were left behind.  
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Appendix 3 
Spectra 
 
 
  
Figure 1: Proton NMR of NN-01 
Figure 2: Carbon 13 NMR spectra 
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Figure 3: dept NMR spectra for NN-01 
Figure 4: NN-01 cosy NMR spectra 
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Figure 5: NN-01 hmbc spectra for NN-01 
Figure 6: NN-01 noesy spectra 
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Figure 7: hsqc spectra for NN-01 
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Figure 8: IR spectra for M. acetate  
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